Mechanistic studies revealed that IL-17A upregulated PD-L1 expression via the IL-17A/P65/NRF1/miR-15b-5p axis at the post-transcriptional level in CRC cells, thereby suppressing the efficacy of immunotherapy. Here, NRF1 is linked to colorectal carcinoma.